Issues
-
Cover Image
Cover Image
Immune-suppressive mechanisms in the tumor microenvironment (TME) are still being defined. By comparing tumors that respond to regulatory T-cell depletion with those that do not, Pires and colleagues find that responding tumors are T-cell enriched and exhibit loss of extracellular matrix (ECM) components. These ECM changes in responding tumors correlate with increased T-cell infiltration and the formation of new lymphatic and vasculature networks. Nonresponding tumors have a significant enrichment of stem cell-like gene signatures compared with responding tumors. The data highlight a role of adaptive immunity in reshaping the TME by altering the ECM and further driving antitumor responses. Read more in this issue on page 1520. Original image from Fig. 5D. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Immunology Research
Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.
Table of Contents
What We’re Reading
In the Spotlight
Cancer Immunology at the Crossroads
Research Articles
Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection
An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression
Correction
Journal Archive
Cancer Immunology Research
(2013-Present)Published monthly since 2013.
(ISSN 2326-6066)
Cancer Immunity
(2001-2013; volumes 1-13)Published periodically from 2001-2013.
(EISSN 1424-9634)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.